- IDEXX Laboratories Inc (NASDAQ:IDXX) reported Q2 revenues of $861 million, an increase of 4% Y/Y on a reported basis and 6.5% on an organic basis, missing the consensus of $864.61 million.
- The growth is driven by Companion Animal Group (CAG) Diagnostics’ recurring revenue growth of 4% reported and 7% organic.
- U.S. same-store clinical visits at veterinary practices declined 3% Y/Y compared to the prior year period clinical visit growth of 13%, which included benefits from increases in new pet ownership during the COVID-19 pandemic.
- The gross margin of 59.7% increased 50 basis points as reported and was flat on a comparable basis.
- The operating margin was 20.8%, down from 31.4%, including a 900 basis point impact related to $80 million in discrete R&D investments, higher travel costs, and inflationary impacts.
- Comparable EPS was $1.58, a decrease of 30% Y/Y, missing the consensus of $1.65.
- Guidance: IDEXX Laboratories lowered its FY22 sales forecast to $3.31 – $3.39 billion, down from $3.39 billion – $3.47 billion and the consensus of $3.42.
- The company forecasts EPS of $7.77 – $8.05, down from earlier guidance of $8.11 – $8.35 and the consensus of $8.27.
- Price Action: IDXX shares are down 3.89% at $382.64 during the market session on the last check Tuesday.
IDEXX Laboratories Misses on Q2 Earnings, Issues FY22 Guidance Below Consensus
IDEXX Laboratories Inc (NASDAQ:IDXX) reported Q2 revenues of $861 million, an increase of 4% Y/Y on a reported basis and…
Related Posts
Disc Medicine Appoints Industry Executive Jean Franchi As Chief Financial Officer, And Promotes Jonathan Yu To Chief Operating Officer
Jean Franchi is an industry veteran and brings over 30 years of leadership experience in finance, investor relations, capital formation, and operations at both development and commercial-stage companiesJonathan Yu,
Faraday Future Shares Plummet On Disappointing FY23 Sales And Nasdaq Compliance Issues
Faraday Future Intelligent Electric Inc. (NASDAQ: FFIE) shares dropped sharply after the company reported disappointing fiscal year 2023 sales results and withdrew its production target guidance.
Bitcoin, Ethereum Investors Remain Hopeful As Crypto Faces Its Worst Year Yet: Benzinga Exclusive Finds
In a recently conducted exclusive survey, Benzinga found that a majority of investors believe it is a good time to invest in cryptocurrencies.